MASHINIi

Heron Therapeutics, Inc..

HRTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing novel, best-in-class therapeutics to address unmet medical needs. The company's product portfolio includes treatments for postoperative pain, cancer-related side effects, and ophthalmic con...Show More

Ethical Profile

Mixed.

Heron Therapeutics (HRTX.US) presents a mixed ethical profile. The company faced a significant data exfiltration incident in February 2024 via the Cencora network, allegedly impacting hundreds of thousands of individuals. While its ZYNRELEF product aims to reduce opioid use post-surgery and patient assistance programs offer up to $0 copays and $200 deductible aid, ZYNRELEF carries a boxed warning for cardiovascular and gastrointestinal risks. CEO compensation reached $10.7 million in 2023, yet employee satisfaction reports a positive 4.4/5 stars on Glassdoor. Critics point to a high ESG risk rating (36.3) and limited verifiable environmental data, despite a stated 12% carbon reduction target by 2025. A settlement with Mylan related to CINVANTI also lacks public details.

Value Scores

Better Health for All30
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect20
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business-30
-100100
Kind to Animals-60
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-80
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

30

Heron Therapeutics demonstrates a commitment to improving patient health through its development and commercialization of therapeutics. ZYNRELEF aims to reduce opioid use after surgery, showing statistically significant reductions in opioid consumption compared to placebo and bupivacaine HCl in clinical trials

1
. The company also partners with the National Academy of Medicine to counter the opioid epidemic
2
. Heron Connect programs offer copay assistance and patient assistance programs (PAPs) for eligible patients, improving access to SUSTOL and CINVANTI
3
,
4
,
5
,
6
. These programs include $0 copays for commercially insured patients and up to $200 in deductible assistance
7
,
8
,
9
. However, ZYNRELEF carries risks of cardiovascular and gastrointestinal events, as highlighted by a boxed warning
10
,
11
. The company also settled with Mylan related to CINVANTI, though details are limited
12
,
13
,
14
. Overall, the focus on improving patient outcomes and access, particularly in pain management and chemotherapy support, supports a positive score. The potential risks associated with some products temper a higher score. The company offers patient assistance programs for Aponvie, Cinvanti, Sustol, and Zynrelef
15
. The majority of the portfolio delivers significant health benefits, with health impact central to the business strategy.
16
,
17
**Assessment Limitations**: The lack of specific quantitative data on long-term effects, side effect frequency, and pricing impacts the confidence level.

Fair Money & Economic Opportunity

0

No evidence available to assess Heron Therapeutics, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

20

Employee satisfaction at Heron Therapeutics is rated at 4.4 out of 5 stars.

1

Fair Trade & Ethical Sourcing

0

No specific, quantitative data was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While the company states a commitment to upholding human rights and complying with laws prohibiting child labor, forced labor, and human trafficking, this is a policy statement and not evidence of the number of substantiated incidents or the results of monitoring.

1
There is no information on fair-trade certification share, supplier audit frequency, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
2

Honest & Fair Business

-30

Heron Therapeutics outlines a compliance program and declares compliance with it and the California Act, which includes an annual dollar limit of $2,500 for gifts.

1
Compliance with Anti-Corruption Laws, including the FCPA and UK Bribery Act, is a condition of a working capital facility agreement.
2

Kind to Animals

-60

Heron Therapeutics conducts comprehensive animal toxicology studies for its Biochronomer technology and includes animal studies in preclinical development to assess product safety and effectiveness.

1
The company is subject to laws and regulations regarding the experimental use of animals.
2
There is no explicit policy to reduce or restrict animal testing, nor any mention of prioritizing alternatives.
3
The company's R&D expense for the three months ended March 31, 2018, was $39.6 million, which constituted approximately 62.2% of its total operating expenses of $63.6 million.
4
However, no specific investment in animal-free technologies or alternatives is disclosed within this R&D budget.
5

No War, No Weapons

0

No evidence available to assess Heron Therapeutics, Inc. on No War, No Weapons.

Planet-Friendly Business

-80

The company uses 22% renewable energy.

1
It has no specific climate-positive initiatives and no science-based carbon reduction targets.
2
No net-zero target year has been declared, and there is no TCFD alignment, climate scenario analysis, or transparency regarding stranded asset risks.
3
No specific environmental compliance violations or fines have been mentioned.
4

Respect for Cultures & Communities

0

No evidence available to assess Heron Therapeutics, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

Heron Therapeutics' privacy policy details user choices for managing personal information, including opting out of marketing communications, managing cookies, and exercising CCPA rights such as the right to know, access, deletion, correction, and opting out of sales/sharing.

1
The company states it complies with applicable privacy laws, including CCPA.
2
The policy also describes data collection and retention practices, noting that data is retained as long as necessary for the purposes for which it was collected or as required by law.
3

Zero Waste & Sustainable Products

0

There is no publicly available data on Heron Therapeutics' waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, or circular design principles.

1
The company also does not provide information on waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, or zero waste certifications.
2
No data is available regarding waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
3

Own Heron Therapeutics, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.